SCHEDULE: Orca Capital Discloses 9.9% Stake in Co-Diagnostics

Orca Capital AG has reported a 9.9% beneficial ownership stake in Co-Diagnostics, Inc., holding 4,809,500 shares of common stock.

Summary

• Orca Capital AG, a German entity, has filed a Schedule 13G indicating beneficial ownership in Co-Diagnostics, Inc.
• Orca Capital AG beneficially owns 4,809,500 shares of Co-Diagnostics, Inc. Common Stock, par value $0.001 per share.
• This ownership represents 9.9% of the total outstanding Common Stock of Co-Diagnostics, Inc.
• The percentage is calculated based on an aggregate of 48,142,582 shares of Common Stock outstanding, which includes the effect of the Issuer's registered offering completed on or before September 18, 2025.
• Orca Capital AG holds sole voting power and sole dispositive power over all 4,809,500 shares.
• The securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of Co-Diagnostics, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake is generally viewed as a neutral to slightly positive signal, indicating institutional interest and transparency, without providing specific operational or financial performance details.

Positives

• Disclosure of a significant institutional investment by Orca Capital AG, indicating potential confidence in Co-Diagnostics, Inc.
• Increased transparency provided to the market regarding a substantial shareholder.

Risks

• This filing, a Schedule 13G, is solely for beneficial ownership disclosure and does not contain information regarding specific operational, financial, or market risks pertinent to Co-Diagnostics, Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Co-Diagnostics, Inc.'s future performance, strategic direction, or operational outlook.

Management Comments

• The filing includes a certification from Thomas Konig, Director of Orca Capital AG, stating that the securities were not acquired or held for the purpose of changing or influencing the control of Co-Diagnostics, Inc.

Industry Context

This filing represents a standard regulatory disclosure of a significant passive institutional investment in a publicly traded company. Such disclosures provide transparency to the market regarding major shareholders and can sometimes signal institutional confidence in the company's long-term prospects within its industry.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for beneficial ownership exceeding 5% and does not provide information for a direct comparison of Co-Diagnostics, Inc.'s operational or financial results against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders benefit from increased transparency regarding the company's ownership structure.
• The presence of a significant institutional investor like Orca Capital AG may be perceived positively by other investors, potentially influencing market sentiment.

Next Steps

• The filing does not specify any immediate future actions, events, or milestones for Co-Diagnostics, Inc. or Orca Capital AG beyond this ownership disclosure.

Key Dates

Keywords

Co-Diagnostics, Orca Capital AG, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake, 189763105